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Abstract  
The authors describe a case report characterised by asymptomatic papules and non-tender subcutaneous 
nodules as the isolated manifestations of gout. 
 
Introduction 
 
Gout is a metabolic, well-known disorder, 
which first descriptions had been reported since the 
ancient time [1]. Although its prevalence varies among 
different populations and racial groups, recent 
epidemiological data underline how gout is becoming 
progressively common in the Western countries, with 
an estimated worldwide prevalence of 2.5-3.9%. It is 
more commonly described in male and adult-
senescent patients [2-4]. 
Gout is caused by disordered purine 
metabolism, resulting in a hyperuricemic condition, 
which is defined by an increase in the serum level of 
uric acid over 7.2 mg/dL. The disease may derive by 
an overproduction of uric acid (primary gout), by an 
increased production of a purine or by a decreased 
excretion of uric acid (secondary gout). Well, known 
risk factors are obesity, alcohol consumption, purine-
rich diet. Additionally, the intake of thiazide diuretics or 
cyclosporine increases the risk to develop gout [1,5]. 
A persistent hyperuricemia leads to the 
accumulation and aggregation of monosodium urate 
monohydrate (MSUM) crystals, also known as tophi. 
Tophi gradually deposit and accumulate in the 
synovial fluid and, less commonly, in other tissue [6]. 
Cutaneous symptoms may lead to diagnosis [7]. 
 
Case report 
An overweight, 61-year-old male subject, 
doctor in general medicine, referred to us with multiple 
papules and subcutaneous, non-tender, pink-reddish 
in colour, nodules. Lesions were symmetrically 
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distributed in the skin upon the elbow of both arms 
and averaged from 0.2 to 1.3 cm in diameter (Fig.1-2). 
Both papules and nodules were completely 
asymptomatic, and they were present by more than 
three months. No other signs, both local and systemic, 
of infection or inflammation were detected. The patient 
denied a history of any form of arthropathy. 
There were no hints to local trauma, infections 
or contact with local irritants. 
The patient suffered from a mild form of 
hypertension, treated with a thiazide diuretic. He 
showed no familiarity for dermatologic and 
rheumatologic diseases. 
The patient did not refer previous treatments 
of the lesion, except for 15-days of topical 
corticosteroid and antibiotics (betamethasone plus 
gentamicin cream), without any beneficial effects. 
 
Figure 1: Asymptomatic papules and nodules, pink-reddish in 
colour, in the skin upon the right elbow 
 
During the clinical evaluation, no other lesions 
were observed in any other part of the body. A 
rheumatologic evaluation showed no apparent joint 
involvement. Routine blood testing for inflammation, 
infections and autoimmune diseases (ANA, 
rheumatoid factor, antiphospholipid antibodies) were 
negative. An excisional biopsy was performed. The 
histopathological diagnosis of gout tophi was made, 
which is negatively birefringent under polarised light. 
Based on the histologic finding, the patient performed 
an additional laboratory test for uric acid and 
underwent to an orthopaedic evaluation. While the 
uric acid resulted to be elevated (15.0 mg/dL), 
confirming the diagnosis of hyperuricemia, the clinical 
and X-ray evaluation of the arms, did not show any 
signs of arthropathy. 
Because of the diagnosis of gout, the patient 
started a diet poor of purines and changed the 
thiazide diuretic treatment with a beta-blocker drug. 
 
Figure 2: The same cutaneous lesions on the left arm 
 
 
Finally, he started a proper therapy with 
allopurinol 300 mg/die. 
 
 
Discussion 
 
The main clinical characteristic of gout is the 
arthropathy, due to the deposition of tophi. Even if the 
great toe is the most commonly affected (podagra), 
other finger joints, as well as ankle and wrist may also 
be involved. Initially, there is a typical joint 
inflammation, characterised by severe pain, erythema 
and oedema [7]. In some cases, the inflammation of 
the synovial-based structures (e.g. bursae and 
tendon) has been described too. If not properly 
diagnosed and treated, gout arthropathy leads to 
affect multiple joints, becoming destructive and 
disabling [8]. 
Some patients may present the MSUM 
crystals deposition in the renal system. The 
phenomenon may vary from a mild and asymptomatic 
urolithiasis to a severe renal failure [9]. 
Although rarely, tophi have been reported in 
other body sites, such as nasal and thyroid cartilages, 
vocal cords, eyelids, cornea, mitral and tricuspid 
valves, hyoid bone and spine [10, 11]. 
Patients with gout may also present a 
cutaneous involvement, characterised by the 
development of intradermal or subcutaneous nodules 
as a sign of the tophi deposition. They are typically 
described in avascular tissues, such as in the ears 
(helix and antihelix areas) or in the periarticular acral 
areas, where they are often associated with an 
involvement of bursae or tendons [12, 13]. 
Less commonly, pustules or ulcerations have 
been described [14]. Rarely, a panniculitis has been 
reported as a sign of gout. Clinically it is characterised 
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by nodular lesions, which may ulcerate. It represents 
an inflammation of the lobular subcutaneous tissue, 
due to the tophi depositions. Even if lesions may have 
different localisations, more commonly they are 
detected on the legs or the trunk [15] 
Another rare skin manifestation is the miliarial 
cutaneous gout (or disseminated one), which is 
characterised by the diffuse deposition of tophi all 
over the skin [16,17]. 
The diagnosis of gout is clinically supported 
by specific tests. The clinical recognition of tophi is 
highly suggestive for gout. A synovial aspiration [7] 
may be useful to detect the presence of MSUM and to 
exclude the presence of infection. Also, an X-ray may 
be performed to for the diagnosis of chronic gout [18]. 
The histologic examination of a lesional biopsy and 
the laboratory test for the uric acid, lead to the 
definitive diagnosis. 
The principal treatment goals in chronic gout 
are (a) the symptomatic treatment of the acute joint 
inflammation and (b) the causal treatment of the 
underlying metabolic cause, the hyperuricemia. Acute 
gout should be treated by non-steroidal anti-
inflammatory agents (NSAIDs) or cyclooxygenase-2 
inhibitors, such as colchicines, and corticosteroids. 
Even if different medical therapies are available to 
regulate the uric acid concentration, allopurinol is 
considered as the first line drug. It acts inhibiting the 
production of uric acid. A valid alternative to 
allopurinol is probenecid, which increases the renal 
excretion of uric acid, by the inhibition of its 
reabsorption. Recently, febuxostat has been 
introduced for the treatment of gout. Like allopurinol, it 
stops the uric acid production by the inhibition of the 
xanthine oxidase [19]. All these treatments aim to 
lower the concentration of serum uric acid levels 
below 360 µmol/L (6 mg/dL). 
Surgical removal of tophi is recommended 
only in patients with severe pain, joint deformities, or 
cutaneous lesions which tend to enlarge or ulcerate 
[20]. More recently, a new technique based on Metal-
assisted and microwave-accelerated decrystallization 
(MAMAD), has been proposed for gout’s treatment 
[21]. 
In conclusion, gout is an important metabolic 
disease, which derives by a hyperuricemia condition. 
Even if the arthropathy, due to the deposition of tophi, 
is most common sign of gout, the disorder may have 
different clinical manifestations. A proper diagnosis 
and treatment are fundamental to avoid the chronic 
course of the disease, which is characterised by 
disabling arthropathies, and by the risk of renal failure 
and cutaneous morbidities. 
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